These high levels of alteration in the PI3K/AKT/PTEN pathway indicate a potential issue for Par-4 activity, because of AKT1 negative regulation, in endometrial and ovarian cancers and are also known for being important key protein related to the chemoresistance of the feminine cancers [5, 6, 30–32]. The gene discussed is PAWR; the disease is ovarian carcinoma.